Cardinal Health (CAH Quick QuoteCAH - Free Report) reported $60.16 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.5%. EPS of $2.08 for the same period compares to $1.84 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $60.67 billion, representing a surprise of -0.84%. The company delivered an EPS surprise of +2.46%, with the consensus EPS estimate being $2.03.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Cardinal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Pharmaceutical and Specialty Solutions: $55.37 billion versus the four-analyst average estimate of $55.86 billion. The reported number represents a year-over-year change of -0.4%.
• Revenue- Corporate: $-21 million versus $-21.65 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -12.5% change.
• Revenue- Other: $1.61 billion compared to the $1.57 billion average estimate based on four analysts. The reported number represents a change of +37.3% year over year.
• Revenue- Medical Products and Distribution: $3.2 billion compared to the $3.21 billion average estimate based on four analysts. The reported number represents a change of +2.9% year over year.
• Segment profit- Pharmaceutical and Specialty Solutions: $535 million versus $543.86 million estimated by four analysts on average.
• Segment profit- Other: $160 million versus the four-analyst average estimate of $147.91 million.
• Segment profit- Global Medical Products and Distribution: $70 million versus $65.48 million estimated by four analysts on average.

View all Key Company Metrics for Cardinal here>>>

Shares of Cardinal have returned -2.5% over the past month versus the Zacks S&P 500 composite's +2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.